1. Akgullu C., Ozdemir B., Yilmaz Y. et al. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease // Acta Cardiol.– 2008.– Vol. 63.– Р. 467–471.
2. Ayers K., Byrne L.M., DeMatteo A., Brown N.J. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome // Hypertension.– 2012.– Vol. 59.– Р. 893–898.
3. Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA.– 2004.– Vol. 292.– Р. 2227–2236.
4. Boutouyrie P., Tropeano A.I., Asmar R. et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study // Hypertension.– 2002.– Vol. 39.– Р. 10–15.
5. Davies J., Carr E., Band M. et al. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? // J. Renin. Angiotensin. Aldosterone Syst.– 2005.– Vol. 6.– Р. 151–153.
6. Dessy C., Moniotte S., Ghisdal P. et al. Endothelial beta3- adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization // Circulation.– 2004.– Vol. 110.– Р. 948–954.
7. Dhakam Z., McEniery C.M., Yasmin et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity // Am. J. Hypertens.– 2006.– Vol. 19.– Р. 214–219.
8. Garban H.J., Buga G.M., Ignarro L.J. Estrogen receptormediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation // J. Cardiovasc. Pharmacol.– 2004.– Vol. 43.– Р. 638– 644.
9. Hirata K., Vlachopoulos C., Adji A., O’Rourke M.F. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? // J Hypertens.– 2005.– Vol. 23.– Р. 551– 556.
10. Kampus P., Serg M., Kals J. et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. // Hypertension.– 2011.– Vol. 57.– Р. 1122–1128.
11. Khan B.V. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function // Adv. Cardiovasc. Dis.– 2011.– Vol. 5.– Р. 241–273.
12. Kocyigit I., Kaya M.G., Orscelik O. et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients // Am. J. Nephrol.– 2012.– Vol. 36.– Р. 11–18.
13. Ladage D., Brixius K., Hoyer H. et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells // Clin. Exp. Pharmacol. Physiol.– 2006.– Vol. 33.– P. 720–724.
14. Laurent S., Cockcroft J., Van Bortel L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications // Eur. Heart J.– 2006.– Vol. 27.– Р. 2588– 2605.
15. Mahmud A., Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection // Am. J. Hypertens.– 2008.– Vol. 21.– Р. 663–667.
16. Manolis A.J., Iraklianou S., Pittaras A. et al. Arterial compliance changes in diabetic normotensive patients after angiotensin- converting enzyme inhibition therapy // Am. J. Hypertens.– 2005.– Vol. 18.– Р. 18–22.
17. Manrique C., Whaley-Connell A., Sowers J.R. Nebivolol in obese and non-obese hypertensive patients // J. Clin. Hypertens. (Greenwich).– 2009.– Vol. 11.– Р. 309–315.
18. Mason R.P., Kalinowski L., Jacob R.F. et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans // Circulation.– 2005.– Vol. 112.– Р. 3795–3801.
19. Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure // Am. J. Hypertens. 2004.– Vol. 17.– Р. 118–123.
20. Oelze M., Daiber A., Brandes R.P. et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats // Hypertension.– 2006.– Vol. 48.– Р. 677–684.
21. Pasini A.F., Garbin U., Stranieri C. et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients // Am. J. Hypertens.– 2008.– Vol. 21.– Р. 1251–1257.
22. Peralta C.A., Norris K.C., Li S. et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP) // Arch. Intern. Med.– 2012.– Vol. 172.– Р. 41–47.
23. Rizos E.C., Agouridis A.P., Elisaf M.S. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review // Curr. Vasc. Pharmacol.– 2010.– Vol. 8.– Р. 638–644.
24. Sarafidis P.A., Bakris G.L. Antihypertensive treatment with betablockers and the spectrum of glycaemic control // QJM.– 2006.– Vol. 99.– Р. 431–436.
25. Schram M.T., Henry R.M., van Dijk R.A. et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study // Hypertension.– 2004.– Vol. 43.– Р. 176–181.
26. Tzemos N., Lim P.O., MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study // Circulation.– 2001.– Vol. 104.– Р. 511–514.
27. Warmack T.S., Estes M.A., Heldenbrand S., Franks A.M. Betaadrenergic antagonists in hypertension: a review of the evidence // Ann. Pharmacother. – 2009.– Vol. 43.– Р. 2031–2043.
28. Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation.– 2006.– Vol. 113.– Р. 1213–1225.